FMC Corporation has submitted its regulatory dossier for rimisoxafen to Brazilian authorities, taking the company’s next-generation herbicide into its second global regulatory review.
The move comes as Brazilian growers confront intensifying weed-resistance challenges in two of the country’s biggest crops. Brazil has approximately 50 million hectares of soybeans and more than 20 million hectares of corn in production.
Among the growing threats are Amaranthus hybridus, which has developed resistance to glyphosate and acetolactate synthase inhibitors, and Amaranthus palmeri, a regulated quarantine weed that poses a significant and growing threat to crop productivity.
“Brazilian growers are facing complex weed resistance challenges that demand new and differentiated solutions,” said Leonardo Bastos, vice president and chief marketing officer at FMC. “Submitting rimisoxafen for regulatory review in Brazil is an important step forward, demonstrating our long-term commitment to this market and to the growers who depend on innovation to protect their crops and their livelihoods.”
Classified by the Herbicide Resistance Action Committee under Groups 12 and 32, rimisoxafen is intended to give growers a new option for diversifying weed-management programs and strengthening long-term resistance management.
FMC said extensive field testing has demonstrated consistent activity against small-seeded broadleaf weeds, including populations resistant to other herbicides such as Amaranthus palmeri and Amaranthus hybridus.
Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in Brazil, following Isoflex active and Dodhylex active. The company said the filings highlight the depth of its research and development pipeline and its focus on bringing next-generation crop protection technologies through the regulatory process.
FMC expects formulated product submissions for rimisoxafen to follow as the Brazilian regulatory process advances. The timing and outcome remain subject to regulatory review and approval.
Rimisoxafen is not currently registered for sale or use in Brazil or any other country. FMC said no offer for sale, sale or use of the product is permitted before all required regulatory approvals are received.
